Drug Trial Radar · NCT03373903
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
Last checked: Nov 19, 2026Latest source record: May 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
652
Actual
Start
Nov 15, 2017
Primary completion
May 3, 2018
Study completion Jul 2018
Sponsor
- Lead sponsor
- Restorbio Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in elderly subjects.
Conditions
- Respiratory Tract Infections
Interventions
PlaceboOther
oral
BEZ235Drug
oral
BEZ235 plus everolimus (RAD001)Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of subjects with 1 or more laboratory-confirmed RTIs through Week 16Time frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Heartland Research Associates
Wichita, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.